Compare TNL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | TVTX |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 2006 | 2013 |
| Metric | TNL | TVTX |
|---|---|---|
| Price | $79.28 | $65.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $84.00 | $40.62 |
| AVG Volume (30 Days) | 833.7K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $4,021,000,000.00 | N/A |
| Revenue This Year | $3.56 | $44.76 |
| Revenue Next Year | $3.55 | $35.51 |
| P/E Ratio | $26.55 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $57.79 | $15.60 |
| 52 Week High | $81.00 | $60.10 |
| Indicator | TNL | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | N/A |
| Support Level | $71.58 | N/A |
| Resistance Level | $81.00 | N/A |
| Average True Range (ATR) | 2.22 | 0.00 |
| MACD | 0.31 | 0.00 |
| Stochastic Oscillator | 99.71 | 0.00 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.